Video

Dr. Jabbour on Front-Line Treatments for CML

Author(s):

Elias Jabbour, MD

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for chronic myelogenous leukemia, at the 2010 ASCO Annual Meeting.

Related Videos
Yungan Tao, MD
Jared Weiss, MD
Guru P. Sonpavde, MD
Martin H. Voss, MD
Sally Lau, MD
Hope S. Rugo, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Srikala Sridhar, MD, MSc, FRCPC
Related Content
Ahmed Hamdy, MD, chief executive officer, Vincerx
October 11th 2024

VIP943 Generates Early Complete Responses, Is Safe in Advanced CD123+ Hematologic Malignancies

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Helen Collins, MD, Enliven Therapeutics
October 7th 2024

ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Steven A. Shallcross
October 3rd 2024

Ribaxamase Shows Safety in the Prevention of aGVHD Following Allo-HSCT

Shyam A. Patel, MD,PhD
September 27th 2024

Meta-Analysis Reveals Potential Role of Clonal Hematopoiesis on Allogeneic and Autologous HSCT Outcomes